



10th February, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers, 1st Floor,
Dalal Street, Mumbai – 400001
BSE Scrip Code: 512463

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
NSE Symbol: LLOYDSENT

Sub: Newspaper Publication of Extract of Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended 31st December, 2025.

Ref: Pursuant to Regulation 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we have enclosed herewith the newspaper clippings of the extract of Unaudited (Standalone & Consolidated) Financial Results for the quarter and nine months ended 31st December, 2025, published in newspapers - Business Standard (English-All Editions) and Mumbai Lakshadweep (Marathi), on Tuesday, 10th February, 2026.

The said advertisements will also be made available on the website of the company at www.lloydsenterprises.in.

We request you to kindly take the same on record.

Thanking You,
Yours Faithfully,

For Lloyds Enterprises Limited

Pranjal Mahapure
Company Secretary and Compliance Officer
ACS69408

Encl: as above

LLOYDS ENTERPRISES LIMITED

Registered Address: A-2, 2nd Floor, Madhu Estate, Pandurang Budhkar Marg, Lower Parel, Mumbai – 400013
Tel: 022 - 6291 8111 Email: lloydsenterprises@lloyds.in Website: www.lloydsenterprises.in
(CIN) L27100MH1986PLC041252

Chola Cholamandalam Financial Holdings Limited
 Financial Holdings 
 CIN: L65100TN1949PLC002905
 Regd. Office: 'Dare House', No.234, N.S.C. Bose Road, Chennai - 600 001.
 Tel: 044 - 40907638 / 25306486; Email: investorservices@cfhl.murugappa.com;
 Website: www.cholafhl.com

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

The Board of Directors of the Company at their meeting held on February 9, 2026, approved the un-audited financial results for the quarter and nine months ended December 31, 2025. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the results have been submitted to the stock exchanges and are available on their websites, www.bseindia.com and www.nseindia.com and also posted on the Company's website at <https://cholafhl.com/investors/qreports> which can be accessed by scanning the Quick Response Code.



For and on behalf of the Board

M M Murugappan
 Chairman
 DIN: 00170478

Place : Chennai
 Date : February 9, 2026

LLOYDS ENTERPRISES LIMITED
 ENTERPRISES 
 Registered Address: A-2, 2nd Floor, Madhu Estate, Pandurang Budhkar Marg, Lower Parel, Mumbai - 400013
 Tel: 022 - 6291 8111 Email: lloydsenterprises@lloyds.in www.lloydsenterprises.in
 (CIN) L27100MH1986PLC041252

EXTRACT OF STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2025
 (Rs. in Crores, except per share data)

Sr. No.	Particulars	Standalone						Consolidated					
		Quarter ended		Nine Months Ended		Year ended	Quarter ended		Nine Months Ended		Year ended		
		31 st December, 2025	30 th September, 2025	31 st December, 2024	31 st December, 2024	31 st March, 2025	31 st December, 2025	30 th September, 2025	31 st December, 2024	31 st December, 2024	31 st March, 2025		
1	Total Income from Operations	51.03	125.24	25.26	540.53	384.41	626.76	333.61	446.66	308.39	1,393.28	1,044.26	1,570.93
2	Net Profit / (Loss) for the period (Before Tax, Exceptional and/or Extraordinary items)	(3.22)	28.51	0.21	285.71	14.70	18.31	39.88	53.53	53.22	380.95	121.29	163.15
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(3.22)	28.51	0.21	285.71	14.70	18.31	39.28	53.53	53.22	380.35	121.29	163.15
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(4.68)	30.05	0.12	246.64	14.60	16.43	37.93	61.84	41.42	348.44	98.82	123.39
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	40.26	(991.23)	277.12	155.07	2,377.38	1,221.87	151.28	(528.73)	523.94	371.03	1126.78	983.22
6	Equity Share Capital (Face Value Re.1/- per share)	139.93	139.93	127.21	139.93	127.21	127.21	139.93	139.93	127.21	139.93	127.21	127.21
7	Other Equity as shown in the Audited Balance Sheet	-	-	-	-	-	4,530.44	-	-	-	-	-	2,893.45
8	Basic & Diluted Earnings Per Share (not annualised) (in Rs.)	(0.04)	0.23	0.00	1.86	0.11	0.13	0.29	0.48	0.33	2.63	0.78	0.97

Notes :
 1. The above is an extract of the detailed format of Unaudited Standalone and Consolidated Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by circular No. CIR/CFD/FAC/62/2016. The full format of the Unaudited Financial Results are available on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com and also on the Company's website at www.lloydsenterprises.in.
 2. The above Financial Results were reviewed and recommended by the Audit Committee and have been approved and taken on record by the Board of Directors at its meeting held on Monday, 9th February, 2026.
 3. The full format of aforesaid Financial Results can also be accessed by scanning the below given QR code.



For and on behalf of the Board
 Lloyds Enterprises Limited
 Sd/-
 Babulal Agarwal
 Chairman & Managing Director
 DIN: 00029389

Date: 9th February, 2026
 Place: Mumbai

AMIS
 apollo microsystems

Apollo Micro Systems Limited
 (CIN: L72200TG1997PLC026556)
 Registered office: Plot No. 128/A, Road No. 12, BEL Road, IDA Mallapur, Hyderabad - 500076, Telangana.
 Telephone: +91 40 27167000 - 99; Fax: +91 40 2715 0820; E-mail: cs@apollo-micro.com; Website: www.apollo-micro.com

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025
 All amounts in lakhs except otherwise stated

Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
Total Revenue from Operations	25,222.01	22,526.45	14,839.35	61,106.76	40,030.25	56,206.92
Profit before exceptional items & tax	3,156.64	4,314.90	2,619.04	10,000.39	6,054.97	8,254.64
Net Profit for the period before tax	3,156.64	4,314.90	2,619.04	10,000.39	6,054.97	8,254.64
Net Profit for the period after tax	2,288.09	3,002.71	1,823.87	7,059.25	4,239.69	5,635.76
Total comprehensive income for the period	2,299.08	3,002.71	1,823.87	7,070.24	4,239.69	5,621.52
Paid up equity share capital	3,572.92	3,356.40	3,064.90	3,572.92	3,064.90	3,064.90
Other equity	-	-	-	-	-	57,692.03
Earnings per share	(Face Value ₹ 1/- each)					
(a) Basic	0.69	0.93	0.60	2.13	1.40	1.86
(a) Diluted	0.68	0.88	0.60	2.09	1.40	1.86

Key numbers of Unaudited Standalone Financial Results of the Company are as under:-

Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
Total Revenue from Operations	20,078.39	22,526.45	14,839.35	55,963.14	40,030.25	56,206.92
Profit before exceptional items & tax	4,385.82	4,751.99	2,647.92	11,920.06	6,129.34	8,380.43
Profit before tax	4,385.82	4,751.99	2,647.92	11,920.06	6,129.34	8,380.43
Profit after tax	3,066.03	3,304.56	1,844.34	8,313.15	4,292.40	5,724.16
Total Comprehensive income	3,081.08	3,304.56	1,844.34	8,328.20	4,292.40	5,709.91
Paid up equity share capital	3,572.92	3,356.40	3,064.90	3,572.92	3,064.90	3,064.90
Other equity	-	-	-	-	-	57,797.00
Earnings per share	(Face Value ₹ 1/- each)					
(a) Basic	0.93	1.02	0.61	2.51	1.42	1.89
(a) Diluted	0.91	0.97	0.61	2.47	1.42	1.89

Notes:
 1. The unaudited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
 2. The above is an extract of the detailed format of unaudited consolidated financial results for the quarter and nine months ended 31 December 2025 filed with the stock exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results (standalone and consolidated) for the quarter and nine months ended 31 December 2025 is available on the Company's website i.e. www.apollo-micro.com under Investor Information section and on the stock exchange websites i.e. www.bseindia.com and www.nseindia.com. The same can be accessed by scanning the QR code provide below:



For and on behalf of the Board of Directors of Apollo Micro Systems Limited
 Sd/-
 Karunakar Reddy Baddam
 Managing Director
 DIN: 00790139

Place: Hyderabad
 Date : 9th February, 2026

Embassy Reit looks to sharpen GCC focus

Expects GCCs to make up to 75% of portfolio in 2 yrs

ANEKA CHATTERJEE
 Bengaluru, 9 February

Bengaluru-headquartered Embassy Office Parks Reit is sharpening its focus on global capability centres (GCCs), targeting GCCs to make up to 75 per cent of its overall portfolio over the next two years.

GCC clients already constitute 65 per cent of its portfolio. Amit Shetty, CEO, Embassy Office Parks Reit, said the mix is expected to move decisively higher as multinational firms expand their India presence to tap the country's technology, data science and artificial intelligence talent pool.

"That growth velocity should play out over the two years. We believe our portfolio will have about 65-70 per cent GCC clients in the same time-frame, driven by continued expansion from both existing centres and new entrants," Shetty told *Business Standard*.

Within the Embassy Reit portfolio, technology firms account for about 30 per cent of GCC tenants, while banking, financial services and insurance (BFSI) contribute around 20-23 per cent. Co-working operators make up roughly 7 per cent, and IT-enabled services (ITes) about 9 per cent.

Moreover, the push comes alongside its strong Q3FY26 performance, with the company reporting a 17 per cent Y-o-Y rise in revenue from operations and a 19 per cent increase in net operating income (NOI), underpinned by steady leasing, higher occupancy and the addition of assets generating cash flow.

Shetty further noted that



“WE BELIEVE THIS (THE REIT MARKET) IS A \$25 BN MARKET TODAY THAT COULD GROW TO \$60-65 BN. THERE IS ENOUGH ROOM FOR EVERYONE”

Amit Shetty,
 CEO, Embassy Office Parks Reit

the improvement in operating metrics reflects several "embedded levers" across the portfolio. Occupancy by value rose to 94 per cent in Q3FY26 from 93 per cent in the previous quarter, supported by 1.1 million square feet of leasing during the quarter.

One such lever, he said, is contracted rental escalations. Embassy Office Parks Reit has secured escalations across 7.2 million square feet for FY26, adding built-in growth to its cash flows. In addition, the Reit is benefiting from assets moving from development to rental yield status.

Shetty remains optimistic on the mid-term outlook for

office leasing, indicating a robust 2025 for the Indian market. Leasing activity during the calendar year touched 82.6 million square feet, while new supply stood at about 57 million square feet, taking India to one billion square feet of total office stock.

He noted that vacancy levels declined to 20 per cent from around 21 per cent. In key micro-markets, vacancies are as low as 5-7 per cent, putting upward pressure on rents. "Across the country, rental rates have firmed up by about 10-12 per cent," he said, adding that industry forecasts point to absorption of 82-85 million square feet annually over the next two years.

In addition, Embassy Reit distributed ₹613 crore to unit holders during the quarter and expects to be on track to meet its full-year guidance for around 10 per cent growth in distributions per unit (DPU).

For FY26, the Reit has guided to 13 per cent growth in NOI and portfolio occupancy of 90-91 per cent by area, translating to about 94 per cent by value.

While Shetty declined to comment on forward-looking projections, he said Embassy Reit's assets under management (AUM) currently stand at around ₹64,000 crore and market capitalisation at ₹42,000 crore.

On the geographical development, Embassy Reit has a pipeline of 7.6 million square feet, requiring an estimated capital expenditure of about ₹4,000 crore. Once stabilised, this pipeline is expected to generate around ₹740 crore of NOI.

Marico to acquire 75% in Vietnamese firm Skinetiq

SHARLEEN D'SOUZA
 Mumbai, 9 February

Marico on Monday announced that its wholly owned subsidiary, Marico South-East Asia Corporation (MSEA), has entered into definitive agreements to acquire 75 per cent equity stake in Vietnamese direct-to-consumer (DTC) firm, Skinetiq Joint Stock Company, based on an equity valuation of ₹350 crore in an all-cash deal.

Skinetiq is a Vietnamese direct-to-consumer company that owns digital-first science-backed skincare brand, 'Candid'. Skinetiq also holds exclusive distribution rights in Vietnam for the skincare brand, Murad.

The deal will be done in two tranches, Marico will pay ₹222.3 crore on receipt of 75 per cent of total shares and in the second tranche, it will pay ₹39.3 crore subject to fulfilment of certain terms and

conditions under the definitive agreements.

It was cofounded in 2020 by Bui Ngoc Anh and Hannah Nguyen (beauty blogger in Vietnam), the company said in an exchange filing.

The filing also said that the transaction aligns with Marico's long term strategy of building a strong premium beauty play in Vietnam, while enabling participation in the country's growing D2C beauty market and also realising various operational synergies.

Saugata Gupta, managing director and chief executive officer, Marico, said, "The investment reflects our commitment to building a strong premium beauty play in Vietnam and advancing our D2C strategy internationally. Vietnam remains a priority market for us, driven by its strong macro-economic fundamentals and rapidly evolving beauty landscape."

Zydus life Q3 net profit up 9%

SOHINI DAS
 Mumbai, 9 February

Ahmedabad-based Zydus Lifesciences posted a 9 per cent year-on-year jump in adjusted net profit for Q3FY26 to ₹110 crore while its revenue from operations jumped 30 per cent to ₹686.45 crore.

The company said that the net profit was adjusted for an exceptional expense of ₹84.9 crore in Q3FY26 being one-time impact of increase in gratuity and leave encashment liability pursuant to New Labour Code enacted by the government, and ₹34.2 crore in acquisition related cost in Q2FY26 including its tax impact.

The Ebitda for the quarter was ₹1816.4 crore up 31 per cent with a resulting Ebitda margin of 26.5 per cent, up 20 bps. The company made a capex spend of ₹463 crore in Q3.

Medtech industry divided on policy for refurbished devices

SANKET KOUL
 New Delhi, 9 February

The Centre's plan to form a new import policy for refurbished high-end medical devices has divided the medtech manufacturing industry. This comes even as imports continue despite a lack of regulation for the devices.

The multinational company (MNC) representative bodies have welcomed the policy review as a means to expand affordable healthcare, while domestic manufacturers say the step could risk patient safety and provide a threat to local manufacturers.

Domestic device makers body Association of Indian Medical Device Industry (AiMeD) on Monday said that they are against any move to reconsider or relax policy curbs on importing refurbished or pre-owned medical equipment, especially without an enforceable regulatory framework benchmarked to global standards.

"Countries like Indonesia, Thailand, China disallow such imports to safeguard public health. India must prioritise

WHILE INDIA'S TOTAL MEDICAL DEVICES WAS ESTIMATED AT AROUND ₹76,000 CRORE IN 2025, THE INDUSTRY SEES AN UNAUTHORISED TRADE WORTH ₹12,000-15,000 CRORE OF PRE-OWNED MEDICAL EQUIPMENT WITHOUT ANY REGULATORY OVERSIGHT

new, indigenously manufactured devices under Make in India. Atmanirbhar Bharat and the Medical Devices Policy (MDR), rather than becoming a dumping ground for end-of-life equipment," Rajiv Nath, forum coordinator, AiMeD added.

However, multinational industry bodies contend that regulated refurbishing of medical equipment can significantly improve patient access, promote healthcare worker training, facilitate component harvesting and ecosystem development and reduce grey market risks.

"Healthcare facilities in Tier-II and Tier-III cities often lack the financial capacity to invest in high-capex equip-

ment. Refurbished devices, available at significantly lower cost, can help bridge this gap," said Pavan Choudary, chairman, Medical Technology Association of India (MTAI).

Valued at around ₹1,500 crore, the pre-owned medical equipment market currently constitutes around 10 per cent of the total medical equipment industry in India.

However, AiMeD representatives claimed that, while India's total medical devices was estimated at around ₹76,000 crore in 2025, the industry sees an unauthorised trade worth ₹12,000-15,000 crore of pre-owned medical equipment without any regulatory oversight.

Globally, regulated markets such as the US and EU permit the use of refurbished medical devices, which account for approximately 7 to 9 per cent of total medical equipment volumes.

Choudary said that as India actively pursues free-trade agreements (FTAs) and Bilateral Trade Agreements (BTAs), it is important to adopt a time-bound, globally aligned policy.

